Works matching IS 00281298 AND DT 2010 AND VI 381 AND IP 3

Results: 8

Novel pharmacological approaches for antiarrhythmic therapy.

Published in:

2010

By:

Ravens, Ursula

Publication type:

Editorial

Cardiac adrenergic control and atrial fibrillation.

Published in:

Naunyn-Schmiedeberg's Archives of Pharmacology, 2010, v. 381, n. 3, p. 235, doi. 10.1007/s00210-009-0474-0

By:

Workman, Antony J.

Publication type:

Article

Improving cardiac gap junction communication as a new antiarrhythmic mechanism: the action of antiarrhythmic peptides.

Published in:

Naunyn-Schmiedeberg's Archives of Pharmacology, 2010, v. 381, n. 3, p. 221, doi. 10.1007/s00210-009-0473-1

By:

Dhein, Stefan;
Hagen, Anja;
Jozwiak, Joanna;
Dietze, Anna;
Garbade, Jens;
Barten, Markus;
Kostelka, Martin;
Mohr, Friedrich-Wilhelm

Publication type:

Article

Atrial Ca2+ signaling in atrial fibrillation as an antiarrhythmic drug target.

Published in:

Naunyn-Schmiedeberg's Archives of Pharmacology, 2010, v. 381, n. 3, p. 195, doi. 10.1007/s00210-009-0457-1

By:

Dobrev, Dobromir

Publication type:

Article

Synthesis and characterisation of NS13558: a new important tool for addressing KCa1.1 channel function ex vivo.

Published in:

Naunyn-Schmiedeberg's Archives of Pharmacology, 2010, v. 381, n. 3, p. 271, doi. 10.1007/s00210-009-0456-2

By:

Bentzen, Bo Hjorth;
Andersen, Rune Wederkinck;
Olesen, Søren-Peter;
Grunnet, Morten;
Nardi, Antonio

Publication type:

Article

The human cardiac K2P3.1 (TASK-1) potassium leak channel is a molecular target for the class III antiarrhythmic drug amiodarone.

Published in:

Naunyn-Schmiedeberg's Archives of Pharmacology, 2010, v. 381, n. 3, p. 261, doi. 10.1007/s00210-009-0454-4

By:

Gierten, Jakob;
Ficker, Eckhard;
Bloehs, Ramona;
Schweizer, Patrick A.;
Zitron, Edgar;
Scholz, Eberhard;
Karle, Christoph;
Katus, Hugo A.;
Thomas, Dierk

Publication type:

Article

Inhibition of IK,ACh current may contribute to clinical efficacy of class I and class III antiarrhythmic drugs in patients with atrial fibrillation.

Published in:

Naunyn-Schmiedeberg's Archives of Pharmacology, 2010, v. 381, n. 3, p. 251, doi. 10.1007/s00210-009-0452-6

By:

Voigt, Niels;
Rozmaritsa, Nadiia;
Trausch, Anne;
Zimniak, Thomasz;
Christ, Torsten;
Wettwer, Erich;
Matschke, Klaus;
Dobrev, Dobromir;
Ravens, Ursula

Publication type:

Article

Primary and secondary prevention of atrial fibrillation with statins and polyunsaturated fatty acids: review of evidence and clinical relevance.

Published in:

Naunyn-Schmiedeberg's Archives of Pharmacology, 2010, v. 381, n. 3, p. 1, doi. 10.1007/s00210-009-0468-y

By:

Savelieva, Irene;
Kourliouros, Antonios;
Camm, John

Publication type:

Article

Works matching IS 00281298 AND DT 2010 AND VI 381 AND IP 3

Novel pharmacological approaches for antiarrhythmic therapy.

Cardiac adrenergic control and atrial fibrillation.

Improving cardiac gap junction communication as a new antiarrhythmic mechanism: the action of antiarrhythmic peptides.

Atrial Ca<sup>2+</sup> signaling in atrial fibrillation as an antiarrhythmic drug target.

Synthesis and characterisation of NS13558: a new important tool for addressing KCa1.1 channel function ex vivo.

The human cardiac K<sub>2P</sub>3.1 (TASK-1) potassium leak channel is a molecular target for the class III antiarrhythmic drug amiodarone.

Inhibition of I<sub>K,ACh</sub> current may contribute to clinical efficacy of class I and class III antiarrhythmic drugs in patients with atrial fibrillation.

Primary and secondary prevention of atrial fibrillation with statins and polyunsaturated fatty acids: review of evidence and clinical relevance.